Sana Biotechnology, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SANA

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to allegations of misleading statements and financial misrepresentation during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from March 17, 2023, to November 4, 2024 [3]. - Allegations include that Sana was at significant risk of insufficient funds to maintain operations and advance product candidates [3]. - Specific product candidates, SC291 in oncology, SC379, and SG299, were claimed to be less promising than represented [3]. - The company was likely to decrease funding for these candidates and reduce headcount to preserve cash for more promising products [3]. - Public statements made by the defendants were alleged to be materially false and misleading throughout the relevant period [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by May 20, 2025, to participate in potential recovery [4]. - Registration will include enrollment in a portfolio monitoring software for status updates on the case [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].